NEWS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

11/18/2024

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

11/14/2024

HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS

10/31/2024

HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE

10/24/2024

Halozyme to Report Third Quarter 2024 Financial and Operating Results

10/23/2024

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®

10/03/2024

Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis

09/13/2024

Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

09/12/2024

Halozyme to Present at Upcoming Investor Conferences

08/28/2024

HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS

08/06/2024
View All Press Releases
All 3
All 3 /Company Updates 1 /Executive Insights 1 /Values Series 1

Insights Value Series: Introduction

April 5, 2022/by ehennes

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

August 9, 2021/by David Anderson

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

January 28, 2021/by David Anderson

Press Releases

  • 05/21/21

    Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®

  • 05/10/21

    Halozyme Reports First Quarter 2021 Results

  • 04/29/21

    Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference

  • 04/20/21

    Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call

  • 02/24/21

    Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027

  • 02/23/21

    Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results

  • 02/10/21

    Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call

  • 01/15/21

    Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis

  • 01/11/21

    Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth

  • 01/04/21

    Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference

Copyright© 2015-2024. Halozyme, Inc. All rights reserved. All trademarks belong to their respective owners.